Abdullah Kutlar, Marvin E Reid, Adlette Inati, Ali T Taher, Miguel R Abboud, Amal El-Beshlawy, George R Buchanan, Hedy Smith, Kenneth I Ataga, Susan P Perrine, Richard G Ghalie
Index: Am. J. Hematol. 88(11) , E255-60, (2013)
Full Text: HTML
2,2-Dimethylbutyrate (HQK-1001), an orally-bioavailable promoter-targeted fetal globin gene-inducing agent, was evaluated in an open-label, randomized dose-escalation study in 52 subjects with hemoglobin SS or S/β(0) thalassemia. HQK-1001 was administered daily for 26 weeks at 30 mg/kg (n = 15), 40 mg/kg (n = 18) and 50 mg/kg (n = 19), either alone (n = 21) or with hydroxyurea (n = 31). The most common drug-related adverse events were usually mild or moderate and reversible. Gastritis was graded as severe in three subjects at 40 mg/kg and was considered the dose-limiting toxicity. Subsequently all subjects were switched to the maximum tolerated dose of 30 mg/kg. Due to early discontinuations for blood transfusions, adverse events or non-compliance, only 25 subjects (48%) completed the study. Drug plasma concentrations were sustained above targeted levels at 30 mg/kg. Increases in fetal hemoglobin (Hb F) were observed in 42 subjects (80%), and 12 (23%) had increases ≥4%. The mean increase in Hb F was 2% [95% confidence interval (CI), 0.8-3.2%] in 21 subjects receiving HQK-1001 alone and 2.7% (95% CI, 1.7-3.8%) in 31 subjects receiving HQK-1001 plus hydroxyurea. Total hemoglobin increased by a mean of 0.65 g/dL (95% CI, 0.5-1.0 g/dL), and 13 subjects (25%) had increases ≥1 g/dL. Future studies are warranted to evaluate the therapeutic potential of HQK-1001 in sickle cell disease. .Copyright © 2013 Wiley Periodicals, Inc.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
2,2-Dimethylbutanoic acid
CAS:595-37-9 |
C6H12O2 |
Liquid chromatography-mass spectrometric assay for quantitat...
2008-02-01 [J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 862(1-2) , 168-74, (2008)] |
[Chemical components of essential oils from the herb of Ligu...
2003-07-01 [Zhongguo Zhong Yao Za Zhi 28(7) , 627-9, (2003)] |
A randomized phase I/II trial of HQK-1001, an oral fetal glo...
2013-05-01 [Br. J. Haematol. 161(4) , 587-93, (2013)] |
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer,...
2012-11-01 [Am. J. Hematol. 87(11) , 1017-21, (2012)] |
Evaluation of safety and pharmacokinetics of sodium 2,2 dime...
2011-08-01 [J. Clin. Pharmacol. 51(8) , 1186-94, (2011)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved